Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 2069-2072

  Gray, Marion A ^a   Delahunt, Brett ^a   Fowles, Jefferson R ^b   Weinstein, Philip ^a   Cooke, Russell R ^c   Nacey, John N ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c Cap and Coast District Health Board ^*  (New Zealand)

Author keywords

Prostate carcinoma; Prostate specific antigen

Indexed keywords

ALPHA 2 MACROGLOBULIN; CHYMOTRYPSIN INHIBITOR; COMPLEXED PROSTATE SPECIFIC ANTIGEN; FREE PROSTATE SPECIFIC ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; TOTAL PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VITAMIN;

ADULT; AGE; AGED; ANALGESIA; ANTIGEN DETECTION; ARTICLE; BODY MASS; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; EDUCATION; ETHNIC DIFFERENCE; EUROPE; FAMILY HISTORY; HUMAN; HUMAN EXPERIMENT; LIFESTYLE; MALE; MAORI; MARRIAGE; NEW ZEALAND; NORMAL HUMAN; PACIFIC ISLANDER; PACIFIC ISLANDS; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; SEXUAL INTERCOURSE; SEXUALITY; SMOKING; SOCIAL ASPECT; SOCIOECONOMICS; VASECTOMY; VITAMIN INTAKE;

ADULT; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES;

EID: 3242741209     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Partin AW: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localised prostate cancer. Urol Clin North Am 23: 531-540, 1996.
2. Mettlin C, Chesley AE, Murphy GP et al: Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39: 153-158, 1999.
3. Horninger W, Rogatsch H, Reissigl A et al: Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 40: 56-61, 1999.
4. Brawer MK, Meyer GE, Letran JL et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52: 3372-3378, 1998.
5. Miller MC, O'Dowd GJ, Partin AW and Veltri RW: Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 57: 1105-1111, 2001.
6. Okegawa T, Noda H, Ohta M et al: Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer. Int J Urol 8: 438-443, 2001.
7. Stamey TA and Yemoto CE: Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 163: 119-26, 2000.
8. Tello FL, Prats CH and Gonzalez MD: Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer. Clin Chem Lab Med 39: 116-120, 2001.
9. Smith DS, Carvalhal GF, Mager DE, Bullock AD and Catalona WJ: Use of lower prostate specific antigen cutoffs for prostate cancer screening on black and white men. J Urol 160: 1732-1738, 1998.
10. Oesterling JE, Jacobsen SL and Klee GG: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
11. Saw S and Aw T: Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population. Pathology 32: 245-249, 2000.
12. Cooney KA, Strawderman MS, Wojno KJ et al: Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 57: 91-96, 2001.
13. Anderson JR, Strickland D, Corbin D, Byrnes JA and Zweiback E: Age-specific reference ranges for serum prostate-specific antigen. Urology 46: 54-57, 1995.
14. Gelmann EP, Chia D, Pinsky PF et al: Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology 58: 561-566, 2001.
15. Kao C: Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males. Anticancer Res 17: 1361-1366, 1997.
16. Fowler JEJ, Sanders J, Bigler SA et al: Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol 163: 1467-1470, 2000.
17. Gray MA, Delahunt B, Fowles JR et al: Assessment of ethnic variation in serum levels of total, complexed and full prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations. Pathology 35: 16-19, 2003.
18. Norrish A: The Auckland Prostate Study: A Case-control Study of the Determinants of Prostate Cancer. Auckland, The University of Auckland, 1997.
19. Kirby RS, Christmas TJ and Brawer M: Prostate Cancer. London, Mosby, 1996.
20. Moore MP and Lunt H: Diabetes in New Zealand. Diabetes Res Clin Pract 50: 65-71, 2000.
21. Statistics New Zealand: Census Tatauranga. 2001 Census. [data online]. Available from: URL: http:#www.stats.govt.nz/; 2002.
22. Norcross WA, Ramirez C and Palinkas LA: The influence of women on the health care-seeking behaviour of men. J Fam Practice 43: 475-80, 1996.
23. Janlert U, Asplund K, Weinehall L, Orth-Gomer K and Unden AL: Men who never married. A socio-medical study in northern Sweden. Arctic Med Res 51: 71-80, 1992.
24. Barry MJ, Fowler FJ Jr, O'Leary MP et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549-57, 1992.
25. Salmond C, Crampton P and Sutton F: NZDep91: A New Zealand index of deprivation. Aust NZ J Public Health 22: 835-837, 1998.
26. Lodding P, Aus G, Bergahl S et al: Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ML prostate specific antigen. J Urol 159: 899-903, 1998.
27. Crawford DE, DeAntoni P, Etzioni R et al: Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. Urology 47: 863-869, 1996.
28. Bangma CH, Kranse R, Blijenberg BG et al: The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 46: 773-778, 1995.
29. Malcolm L: Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders. NZ Med J 109: 356-58, 1996.
30. Sporle A and Pearce N: Impact of changes in the death registration process upon Maori mortality statistics. NZ Med J 112: 411-412, 1999.
31. Sporle A, Pearce N and P Davis: Social class mortality differences in Maori and non-Maori men aged 15-64 during the last two decades. NZ Med J 115: 127-131, 2002.
32. Davis P, Lay-Yee R, Maingay S et al: Patterns of general practitioner usage among Pacific people: indicative results from the Waikato Medical Care Survey 1991-2. NZ Med J 12: 335-336, 1997.
33. Doctors Guide: Daily Aspirin may help ward off prostate cancer. Available from: URL: http://www.docguide.com/news (Mayo Clinic, Rochester, MN), 2002.
34. Nomura AM: Body size and prostate cancer. Epidemiol Rev 23: 126-129, 2001.
35. Hickey K, Do K and Green A: Smoking and prostate cancer. Epidemiol Rev 23: 115-121, 2001.